The Development of Models Based on Linear and Nonlinear Multivariate Methods to Predict ADME/PK Properties Using Physicochemical Properties of Kinase, Protease Inhibitors, and GPCR Antagonists
Oral bioavailability of a drug compound is the significant property for potential drug candidates. Measuring this property can be costly and time-consuming. Quantitative structure-property relationships (QSPRs) are used to estimate the percentage of oral bioavailability, and they are an attractive alternative to experimental measurements. A data set of 217 drug and drug-like compounds with measured values of the percentage of oral bioavailability taken from the small molecule ChemBioBase database was used to develop and test a QSPR model. Descriptors were calculated for the compounds using Codessa 2.1 tool. Nonlinear general regression neural network model was generated using the DTREG predictive modeling program software. The calculated percentage of oral bioavailability model performs well, with root-mean-square (rms) errors of 4.55% oral bioavailability units for the training set, 14.32% oral bioavailability units for the test set, and 19.12% oral bioavailability units for the external prediction set. Given the structural diversity and bias of the data set, this is a good first attempt at modeling oral bioavailability using QSPR methods. The model can be used as a potential virtual screen or property estimator. With a larger data supply less biased toward the high end values of the percentage of oral bioavailability, a more successful model could likely be developed. 1. Introduction Rational drug discovery requires early methods of all factors influencing on the likely success of a drug candidate in the subsequent stages of the drug development. The study of absorption, distribution, metabolism, excretion, and pharmacokinetics (ADME/PK) has become a major discipline in drug discovery through the application of well-established in vitro and in vivo methodologies [1]. PK plays a crucial role in the pharmaceutical research and development and, because of the major role of drug metabolism, drug discovery research in this area is covered by groups coalesced around the name drug metabolism and pharmacokinetics (DMPKs) [2–6]. Elimination is the product of metabolism and excretion. Pharmacokinetics describe how the body reacts to a specific drug after administration. Pharmacokinetic properties of drugs may be affected by factors such as the administration site and the administered drug dose; these may influence the rate of absorption. One more process, liberation, plays an important role in pharmacokinetics: liberation means the release of drug from the formulation [7]. The primary goal of the drug discovery and development process is to find a molecule
References
[1]
P. J. Eddershaw, A. P. Beresford, and M. K. Bayliss, “ADME/PK as part of a rational approach to drug discovery,” Drug Discovery Today, vol. 5, no. 9, pp. 409–414, 2000.
[2]
M. S. Alavijeh and A. M. Palmer, “The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines,” IDrugs, vol. 7, no. 8, pp. 755–763, 2004.
[3]
S. A. Roberts, “Drug metabolism and pharmacokinetics in drug discovery,” Current Opinion in Drug Discovery & Development, vol. 6, pp. 66–80, 2003.
[4]
R. J. Riley, I. J. Martin, and A. E. Cooper, “The influence of DMPK as an integrated partner in modern drug discovery,” Current Drug Metabolism, vol. 3, no. 5, pp. 527–550, 2002.
[5]
J. Lin, D. C. Sahakian, S. M. de Morais, J. J. Xu, R. J. Polzer, and S. M. Winter, “The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery,” Current Topics in Medicinal Chemistry, vol. 3, no. 10, pp. 1125–1154, 2003.
[6]
P. J. Eddershaw, A. P. Beresford, and M. K. Bayliss, “ADME/PK as part of a rational approach to drug discovery,” Drug Discovery Today, vol. 5, no. 9, pp. 409–414, 2000.
[7]
W. A. Ritschel, “The LADMER system: liberation, absorption,distribution, metabolism, elimination and response,” in Handbook of Basic Pharmacokinetics Including Clinical Applications., W. A. Ritschel, Ed., pp. 19–24, Drug Intelligence, Hamilton, Canada, 1992.
[8]
D. P. Nicolau, “Pharmacokinetic and pharmacodynamic properties of meropenem,” Clinical Infectious Diseases, vol. 47, supplement 1, no. 1, pp. S32–S40, 2008.
[9]
W. Tong, D. R. Lowis, R. Perkins et al., “Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor,” Journal of Chemical Information and Modeling, vol. 38, no. 4, pp. 669–677, 1998.
[10]
P. L. Toutain and A. Bousquet-Me'lou, “Bioavailability and its assessment,” Journal of Veterinary Pharmacology and Therapeutics, vol. 27, pp. 455–466, 2004.
[11]
A. Gobbi and M. L. Lee, “DISE: directed sphere exclusion,” Journal of Chemical Information and Computer Sciences, vol. 43, no. 1, pp. 317–323, 2003.
[12]
ChemBioBase, November 2012, http://www.jubilantbiosys.com/index.php/services/functional-discovery-services/discovery-informatics.
[13]
Suite: LigPrep, Version 2.5, Schr?dinger, LLC, New York, NY, USA, 2012.
[14]
A. R. Katritzky, M. Karelson, and R. Petrukhin, “Comprehensive descriptors for structural and statistical,” Tech. Rep. CODESSA PRO Project, 2002.
[15]
D. M. Mudie, G. L. Amidon, and G. E. Amidon, “Physiological parameters for oral delivery and in vitro,” Molecular Pharmaceutics, vol. 7, no. 5, pp. 1388–1405, 2010.
[16]
M. D. Wessel, P. C. Jurs, J. W. Tolan, and S. M. Muskal, “Prediction of human intestinal absorption of drug compounds from molecular structure,” Journal of Chemical Information and Computer Sciences, vol. 38, no. 4, pp. 726–735, 1998.
[17]
C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings,” Advanced Drug Delivery Reviews, vol. 23, pp. 3–25, 1995.
[18]
W. J. Egan, K. M. Merz, and J. J. Baldwin, Prediction of Drug Absorption Using Multivariate Statistics Center for Informatics & Drug Discovery and Pharmacopeia Laboratories, Pharmacopeia, Princeton, NJ, USA, 2000.
[19]
P. Artursson and J. Karlsson, “Correlation between oral drug absorption in humans and apparent drug permeability,” Biochemical and Biophysical Research Communications, vol. 175, no. 3, pp. 880–885, 1991.
[20]
CIMPL 1.0, November 2012, http://www.barissumengen.com/cimpl/.
[21]
M. A. Cabrera-Perez, H. Pham-The, M. Bermejo, I. G. Alvarez, M. G. Alvarez, and T. M. Garrigues, “QSPR in oral bioavailability: specificity or integrality?” Mini-Reviews in Medicinal Chemistry, vol. 12, no. 6, pp. 534–550, 2012.